Quick Comparison
| NAC | Piracetam | |
|---|---|---|
| Half-Life | 5.6 hours | 4-5 hours |
| Typical Dosage | Standard: 600-1800 mg daily in 1-2 divided doses. Clinical (OCD/addiction): 1200-2400 mg daily. Take on an empty stomach for best absorption. Some practitioners combine with Vitamin C to enhance glutathione recycling. | Standard: 1200-4800 mg daily in 2-3 divided doses. Clinical studies commonly use 2400-4800 mg daily. The 'attack dose' protocol uses 4800 mg daily for the first week, then reduces to maintenance. |
| Administration | Oral (capsules, powder). Take on an empty stomach. Unpleasant sulfur taste in powder form. | Oral (powder, capsules, tablets). Highly bioavailable orally with nearly 100% absorption. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
NAC
NAC is deacetylated to cysteine, the rate-limiting substrate for glutathione synthesis via gamma-glutamylcysteine synthetase and glutathione synthetase. Glutathione (GSH) is the primary intracellular antioxidant in neurons, neutralizing reactive oxygen species and maintaining redox balance. NAC also activates the cystine-glutamate antiporter (System Xc-, composed of SLC7A11 and SLC3A2 subunits), which exchanges extracellular cystine for intracellular glutamate in a 1:1 ratio. This non-vesicular mechanism modulates extrasynaptic glutamate levels, reducing NMDA receptor overactivation and excitotoxicity. The glutamate-modulating effect explains NAC's promise in OCD (reducing corticostriatal glutamate hyperactivity), addiction (normalizing nucleus accumbens glutamate after drug exposure), and neurodegenerative conditions involving glutamate dysregulation.
Piracetam
Piracetam modulates AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-methyl-D-aspartate) glutamate receptors through positive allosteric modulation, enhancing excitatory neurotransmission without direct agonism. It increases membrane fluidity of neuronal phospholipid bilayers by reducing membrane microviscosity, which improves ion channel function and signal transmission. Piracetam enhances acetylcholine receptor density and turnover in the hippocampus, upregulating both muscarinic (M1) and nicotinic receptor expression. It potentiates the cholinergic system through increased high-affinity choline uptake. Additionally, piracetam improves cerebral blood flow via nitric oxide-dependent vasodilation and enhances oxygen utilization (glucose metabolism) in aged or hypoxic brain tissue, supporting mitochondrial function.
Risks & Safety
NAC
Common
Nausea, vomiting, diarrhea, foul-smelling breath.
Serious
May interact with blood thinners and nitroglycerin. Concern that antioxidants may reduce efficacy of chemotherapy (theoretical).
Rare
Bronchospasm (in people with asthma), anaphylactic-like reactions.
Piracetam
Common
Headache (often from insufficient choline intake), insomnia if taken late in the day, gastrointestinal discomfort.
Serious
Very rare — piracetam has an extremely favorable safety profile. May increase the effects of blood thinners.
Rare
Nervousness, agitation, weight gain.
Full Profiles
NAC →
N-Acetyl Cysteine is a precursor to glutathione — the body's master antioxidant. In the brain, NAC provides potent neuroprotection against oxidative stress and also modulates glutamate signaling through the cystine-glutamate antiporter. It is used clinically for acetaminophen overdose and is studied for OCD, addiction, and neurodegenerative diseases.
Piracetam →
The original nootropic, synthesized in 1964 by Corneliu Giurgea who coined the term 'nootropic.' Piracetam modulates glutamate and acetylcholine neurotransmission to enhance memory, learning, and cognitive fluidity. Widely prescribed in Europe for cognitive decline and used globally as a cognitive enhancer. One of the most studied nootropics with decades of clinical data.